Unlike other chemicals that have been tested in mammalian germ cells, the t
ype-II topoisomerase inhibitor etoposide exhibits significant mutagenicity
in primary spermatocytes. Because this is the cell stage during which meiot
ic recombination normally occurs, and because topoisomerases play a role in
recombination, we studied the effect of etoposide on crossing-over in male
mice. Exposure to those meiotic prophase stages (probably early to mid-pac
hytene) during which specific-locus deletion mutations can be induced resul
ted in decreased crossing-over in the p-Tyr(c) interval of mouse chromosome
7. Accompanying cytological studies with fluorescent antibodies indicated
that while there was no detectable effect on the number of recombination no
dules (MLH1 foci), there were marked changes in the stage of appearance and
localization of RAD51 and RPA proteins. These temporal and spatial protein
patterns suggest the formation of multiple lesions in the DNA after MLH1 h
as already disappeared from spermatocytes. Since etoposide blocks religatio
n of the cut made by type II topoisomerases, repair of DNA damage may resul
t in rejoining of the original DNA strands, undoing the reciprocal exchange
that had already occurred and resulting in reduced crossing-over despite a
normal frequency of MLH1 foci. Crossing-over could conceivably be affected
differentially in different chromosomal regions. If, however, the predomin
ant action of etoposide is to decrease homologous meiotic recombination, th
e chemical could be expected to increase nondisjunction, an event associate
d with human genetic risk; Three periods in spermatogenesis respond to etop
oside in different ways. Exposure of (a) late differentiating spermatogonia
(and, possibly, preleptotene spermatocytes) results in cell death; (b) ear
ly- to mid-pachytene induces specific-locus deletions and crossover reducti
on; and, (c) late pachytene-through-diakinesis leads to genetically unbalan
ced conceptuses as a result of clastogenic damage. (C) 2000 Elsevier Scienc
e B.V. All rights reserved.